cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
2018; Springer Science+Business Media; Volume: 136; Issue: 5 Linguagem: Inglês
10.1007/s00401-018-1913-0
ISSN1432-0533
AutoresDaniel J. Brat, Kenneth Aldape, Howard Colman, Eric C. Holland, David N. Louis, Robert B. Jenkins, Bette K. Kleinschmidt‐DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp, Andreas von Deimling, Michael Weller,
Tópico(s)Cancer Genomics and Diagnostics
ResumoWorking Committee 1 concluded that histologic grade II and III IDH-wildtype diffuse astrocytic gliomas that contain high-level EGFR amplification, the combination of whole chromosome 7 gain and whole chromosome 10 loss (+7/−10), or TERT promoter mutations, correspond to WHO grade IV and should be referred to as diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. Assessment of classification by DNA methylation profiling and additional +7/−10 signatures appear to be promising as well and could be considered in the future following additional experience and validation. We also concluded that specific molecular signatures in subsets of IDH-wildtype diffuse astrocytic gliomas are associated with better clinical outcomes and should not lead to a high-grade designation, including, but not limited to, those gliomas with MYB/MYBL or BRAF alterations as individual drivers.
Referência(s)